These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cardiovascular effects of estrogen replacement therapy. Chae CU; Manson JE Adv Intern Med; 2001; 47():47-88. PubMed ID: 11795080 [No Abstract] [Full Text] [Related]
3. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Castelo-Branco C; Casals E; Figueras F; Sanjuan A; Vicente JJ; Balasch J; Vanrell JA Menopause; 1999; 6(2):92-7. PubMed ID: 10374214 [TBL] [Abstract][Full Text] [Related]
4. [Lipoprotein(a) and the cardiovascular risk during estrogen-progestin replacement therapy in postmenopause]. Porcelli A; Calleri L; Gallello D; Taccani C; Surico N Minerva Ginecol; 1997; 49(1-2):39-42. PubMed ID: 9162884 [TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? Marcovina SM; Koschinsky ML Circulation; 1999 Sep; 100(11):1151-3. PubMed ID: 10484533 [No Abstract] [Full Text] [Related]
7. Lipoprotein (a): where does the atherogenicity reside? Berglund L J Lab Clin Med; 2002 Mar; 139(3):131-2. PubMed ID: 11944022 [No Abstract] [Full Text] [Related]
8. Tibolone and the serum lipid/lipoprotein profile: does this have a role in cardiovascular protection in postmenopausal women? Ginsburg J; Prelevic GM Menopause; 1999; 6(2):87-9. PubMed ID: 10374212 [No Abstract] [Full Text] [Related]
9. High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms. Anglés-Cano E Circulation; 2000 Dec; 102(25):E184-5. PubMed ID: 11120709 [No Abstract] [Full Text] [Related]
10. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Farish E; Barnes JF; Fletcher CD; Ekevall K; Calder A; Hart DM Menopause; 1999; 6(2):98-104. PubMed ID: 10374215 [TBL] [Abstract][Full Text] [Related]
11. Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Ostberg JE; Damjanovic T; Dimkovic N; Byrne D; Mikhailidis DP; Prelevic GM Fertil Steril; 2004 Jun; 81(6):1624-31. PubMed ID: 15193486 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of electroacupuncture therapy for weight loss changes plasma lipoprotein A, apolipoprotein A and apolipoprotein B levels in obese women. Cabioglu MT; Gündogan N; Ergene N Am J Chin Med; 2008; 36(6):1029-39. PubMed ID: 19051333 [TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options. Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein (a) and apoliprotein (a) isoform size in thyroid disease: the quest for the golden fleece. Duntas LH Thyroid; 2003 Apr; 13(4):345-6. PubMed ID: 12812213 [No Abstract] [Full Text] [Related]
15. Lipoprotein (a) and apolipoprotein (a) in primary antiphospholipid syndrome. Bećarević M; Singh S; Majkić-Singh N Clin Biochem; 2007 Mar; 40(5-6):317-20. PubMed ID: 17291477 [TBL] [Abstract][Full Text] [Related]
16. [Lipoprotein (a) and stroke]. Ferraro M; Spagnuolo V; Sprovieri M; Mauro GF Minerva Med; 2008 Aug; 99(4):399-409. PubMed ID: 18663347 [TBL] [Abstract][Full Text] [Related]
17. Plasma lipids, lipoprotein Lp(a), apolipoproteins, and hemostatic risk factors distributions in postmenopausal women. Cubrilo-Turek M; Stavljenić-Rukavina A; Reiner Z; Zrinski R Acta Med Croatica; 1999; 53(2):61-6. PubMed ID: 10705622 [TBL] [Abstract][Full Text] [Related]
18. [Estrogen-progestin contraception and biohumoral response of new markers of the atheroma risk. Behavior of lipoprotein(a) and apolipoproteins A and B]. Porcelli A; Calleri L; Gallello D; Taccani C; Surico N Minerva Ginecol; 1997 Mar; 49(3):63-6. PubMed ID: 9173339 [TBL] [Abstract][Full Text] [Related]